Creso Pharma Limited
COPHF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $39 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $39 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 69.8% | 60.8% | 0.7% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 71.5% | -88.2% | -141.6% | 149.3% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -25.8% | -315% | -536.3% | 133.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -202.6% | -403.9% | -587.7% | -165.4% |
| EPS Diluted | 7.8 | -7.8 | -10.04 | 10.018 |
| % Growth | 200% | 22.3% | -200.2% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |